Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Patterns in detection of recurrence among patients treated for breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Patients' Experience of Communication During Their Course of Treatment in an Oncology Outpatient Clinic: Qualitative Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining in vitro sensitivity and gene expression with clinical genetic information from > 3000 clinical tumor samples.

METHODS: From a DBCG cohort, 140 consecutive patients were treated with epirubicin between May 1997 and November 2016. After patient informed consent, mRNA was isolated from archival formalin-fixed paraffin-embedded primary breast tumor tissue and analyzed using Affymetrix arrays. Using time to progression (TTP) as primary endpoint, the efficacy of epirubicin was analyzed according to DRP combined with clinicopathological data collected retrospectively from patients' medical records. Statistical analysis was done using Cox proportional hazards model stratified by treatment line.

RESULTS: Median TTP was 9.3 months. The DRP was significantly associated to TTP (P = 0.03). The hazard ratio for DRP scores differing by 50 percentage points was 0.55 (95% CI -0.93, one-sided). A 75% DRP was associated with a median TTP of 13 months compared to 7 months following a 25% DRP. Multivariate analysis showed that DRP was independent of age and number of metastases.

CONCLUSION: The current study prospectively validates the predictive capability of DRP regarding epirubicin previously shown retrospectively allowing the patients predicted to be poor responders to choose more effective alternatives. Randomized prospective studies are needed to demonstrate if such an approach will lead to increased overall survival.

TidsskriftBreast Cancer Research and Treatment
Udgave nummer2
Sider (fra-til)391-400
StatusUdgivet - 2018

ID: 55423734